Literature DB >> 26827699

Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice.

Y Lalami1, A Awada2.   

Abstract

It is now well established that head and neck cancer carcinogenesis is characterized by genetic instability and several immune defects, leading to unique host-tumor interactions. In such condition, recent improved comprehension and relevant findings could lead to identification of innovative molecular therapeutic targets, achieving considerable clinical and translational research. This review aims to summarize and to highlight most recent and relevant scientific rationale in this era of immunotherapy revival, and to correlate it to the near future clinical practice for the management of this challenging disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HPV; Head and neck cancer; Immune system; Immunotherapy; Tumor immune infiltration

Mesh:

Year:  2016        PMID: 26827699     DOI: 10.1016/j.ctrv.2016.01.001

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  4 in total

Review 1.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

Review 2.  Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.

Authors:  Sulsal Haque; Mahender Yellu; Jaskirat Randhawa; Nooshin Hashemi-Sadraei
Journal:  Drug Des Devel Ther       Date:  2017-08-31       Impact factor: 4.162

Review 3.  Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Authors:  Jessica Moskovitz; Jennifer Moy; Robert L Ferris
Journal:  Curr Oncol Rep       Date:  2018-03-03       Impact factor: 5.075

Review 4.  Immunotherapy for head and neck squamous cell carcinoma.

Authors:  Thorsten Fuereder
Journal:  Memo       Date:  2016-06-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.